



2021 session of the Economic and Social Council

[Commission on Narcotic Drugs \(CND\)](#)

[CND input to the 2021 HLPE](#)

[64th session](#) (12 - 16 April 2021), Vienna.

Report of the **Commission on Narcotic Drugs** on its sixty-fourth session [[E/2021/28](#)]

Resolutions/decisions **adopted by the Council** at the 2021 Management Segment (July meetings) **as recommended by the Commission** on its 64th session ([E/2021/28](#), chap. I, sect. A; and [E/2021/SR.13](#))  19(d)  22 July 2021

[Decision 2021/251](#): Report of the Commission on Narcotic Drugs on its sixty-fourth session and provisional agenda for its sixty-fifth session (draft decision I)

[Decision 2021/252](#): Report of the International Narcotics Control Board (draft decision II and [E/INCB/2020/1](#))

Further resolutions and decisions **adopted by CND** on its 64th session ([E/2021/28](#), chap. I, sect. B):

Resolution 64/1: Statement of the Commission on Narcotic Drugs on the impact of the coronavirus disease (COVID-19) pandemic on the implementation of Member States' joint commitments to address and counter all aspects of the world drug problem

Resolution 64/2: Promoting alternative development as a development-oriented drug control strategy, including in the context of the coronavirus disease (COVID-19) pandemic and its consequences

Resolution 64/3: Promoting scientific evidence-based, quality, affordable and comprehensive drug prevention, treatment, sustained recovery and related support services

Resolution 64/4: Improving data collection on, and responses to, the harmful effects of the non-medical use of pharmaceuticals containing narcotic drugs, psychotropic substances or new psychoactive substances

Resolution 64/5: Facilitating access to comprehensive, scientific evidence-based drug demand reduction services and related measures, including for people impacted by social marginalization

Decision 64/1: Inclusion of isotonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol

Decision 64/2: Inclusion of CUMYL-PEGACLONE in Schedule II of the Convention on Psychotropic Substances of 1971

Decision 64/3: Inclusion of MDMA-4en-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971

Decision 64/4: Inclusion of 3-methoxyphencyclidine in Schedule II of the Convention on Psychotropic Substances of 1971



Decision 64/5: Inclusion of diphenidine in Schedule II of the Convention on Psychotropic Substances of 1971

Decision 64/6: Inclusion of clonazepam in Schedule IV of the Convention on Psychotropic Substances of 1971

Decision 64/7: Inclusion of diclazepam in Schedule IV of the Convention on Psychotropic Substances of 1971

Decision 64/8: Inclusion of flubromazolam in Schedule IV of the Convention on Psychotropic Substances of 1971

[Reconvened 63rd session](#) (3 – 4 December 2020), Vienna.

Resolutions/decisions **adopted by the Council** at its [5th plenary meeting](#) as recommended by the Commission at its reconvened 63rd session ([E/2021/28/Add.1](#), chap. I, sect. A, and [E/2021/SR.5](#))  19(d)  24 February 2021

[Decision 2021/218](#): Improving the governance and financial situation of the United Nations Office on Drugs and Crime: extension of the mandate of the standing open ended intergovernmental working group on improving the governance and financial situation of the United Nations Office on Drugs and Crime (draft decision I)

[Decision 2021/220](#): Report of the Commission on Narcotic Drugs on its reconvened sixty-third session (draft decision II)